Why Is TEVA PHARMACEUTICAL ADR (TEVA) Stock Up Today?

Teva Pharmaceutical ADR (TEVA) surged 11.19% to $35.20 on July 29, 2026, driven by a combination of strong Q2 2026 financial results and strategic moves. The company reported record Q2 net sales of $77 million for its key product UZEDY, a 43% year-over-year increase, and raised its 2026 outlook. Additionally, Teva announced plans to seek a direct listing in the U.S., signaling a shift in its capital structure and market presence.

What Happened

Teva’s Q2 2026 report highlighted robust performance from its innovative brands despite a decline in generics revenue. The company reported total Q2 revenue of $4.1 billion, with key innovative brands growing 43% year-over-year. Teva also announced a direct listing of its ordinary shares on the NYSE, effective September 14, 2026, replacing its American Depositary Share program. This move is part of a broader strategy to streamline operations and focus on growth. The company raised its 2026 outlook across all key metrics, including revenue and EBITDA. However, adjusted earnings per share for Q2 came in at $0.02, below the $0.25 estimate, while revenue beat estimates.

What The Data Shows

Teva’s stock opened at $31.46, a 0.7% gap down from the previous close, but quickly reversed to hit a session high of $35.69. The stock traded as low as $31.01 before settling at $34.92. Volume reached 2.4 million shares, or 0.4 times the 3-month daily average. The stock is currently trading within its 52-week range of $14.99 to $37.34. With a market cap of $36.2 billion, a P/E ratio of 23.6, and a beta of 0.86, Teva appears to be gaining traction as it transitions from a generics-focused model to one driven by innovation.

What To Watch

Teva’s updated 2026 guidance and the upcoming direct listing on the NYSE will be key focus areas for investors. The company’s ability to maintain its growth trajectory in innovative products will be critical in the coming quarters.